Struggling to see clearly due to astigmatism and finding it hard to focus up close from presbyopia?. We're changing that with ACUVUE® OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM—the first and only daily disposable contact lens designed to treat both astigmatism and presbyopia.¹

Join our Q1 2025 #earnings call and webcast now: $JNJ

RT @JNJInnovMed: Today we’re breaking ground on our new biologics manufacturing site in Wilson, North Carolina, to help deliver transformat….

We’re expanding U.S. manufacturing, technology and research & development of innovative healthcare solutions to impact health for humanity:

Join our Q4 and full-year 2024 #earnings call and webcast now: $JNJ

We’re proud to be recognized as a top 5 company by @atmindex. See how we're harnessing our capabilities, reach and resources to help people around the world get the care they need:

We're using AI and other innovative technology in new ways to advance healthcare—from improving surgical training and medical procedures to personalizing care for patients around the world. Discover more:

"Together, advances in science and technology will lead to more effective and personalized treatments." Our Chairman & CEO Joaquin Duato took the stage at @HLTHEVENT to share why now is the time for bold ambition in healthcare. #HLTHUSA

How would the world change if everyone had equal access to healthcare? @johnlegend joined our EVP, Global Corporate Affairs, Vanessa Broadhurst, at @HLTHEvent for a powerful conversation on the importance of driving culturally competent care to unlock health equity.

We're at @HLTHEVENT to share how we're using innovative technologies to advance healthcare—including creating more personalized care strategies for patients. Follow along for updates!

We're heading to @HLTHEVENT from October 20-23 to share how we're harnessing innovative technologies to revolutionize healthcare. Swipe to explore what you can learn from our leaders:

See a recap of our Q3 2024 #earnings here: $JNJ

Joe Wolk, Executive Vice President and Chief Financial Officer, #JNJ, on our Q3 2024 #earnings results. Go to our Investor Relations site for more information: $JNJ

Joaquin Duato, Chairman and Chief Executive Officer, #JNJ, on our Q3 2024 #earnings results and financial performance. Read the release for details, non-GAAP reconciliations and cautionary statements: $JNJ

Join our Q3 2024 #earnings call and webcast now: $JNJ

New: We’ve announced our Q3 2024 earnings results. See the press release for full financial details, non-GAAP reconciliations and cautionary statements: $JNJ #earnings.

Join us tomorrow at 8:30 AM ET for a live call and webcast as we share our Q3 2024 results. Register here: $JNJ #earnings

#NEWS: Today we have officially completed our acquisition of V-Wave, a privately-held company developing innovative treatment options for patients with heart failure. Click here for more information:

We’ve entered into an agreement to acquire V-Wave, a company developing innovative treatment options for patients with heart failure. Click here for more information:

See a recap of our Q2 2024 #earnings here: $JNJ